(NRIX) Movement as an Input in Quant Signal Sets
Nurix Therapeutics Inc. (NASDAQ: NRIX) is experiencing divergent sentiment across all time horizons, suggesting choppy market conditions with a mid-channel oscillation pattern. AI models have generated three distinct trading strategies: a Long Position Trading Strategy, a Momentum Breakout Strategy, and a Short Risk Hedging Strategy. The analysis identifies support and resistance levels across near-term, mid-term, and long-term timeframes, with a notable risk-reward short setup targeting 15.6% downside versus 0.3% risk.
An officer proposes selling 5,786 shares of Nurix Therapeutics (NRIX).
An officer of Nurix Therapeutics, Christine Ring, has proposed selling 5,786 common shares valued at approximately $135,045, acquired through stock option exercises. This proposed sale, scheduled for October 2, 2026, follows several prior 10b5-1 sales and another sale in July, indicating ongoing insider activity. The filing provides details on the transaction and includes a representation that no material adverse information is known regarding the company.
NRIX Q3'26 Earnings: revenue estimate is 24.35M USD
Nurix Therapeutics, Inc. (NRIX) is slated to release its Q3'26 earnings on October 9th, with a revenue estimate of $24.35 million and an anticipated EPS of ($0.60). The article provides a detailed table comparing reported and estimated revenue and EPS for several quarters, highlighting past surprises.
Nurix Therapeutics (NRIX) Projected to Post Earnings on Thursday
Nurix Therapeutics (NASDAQ:NRIX) is expected to report its Q3 2026 earnings after market close on Thursday, October 8th, with analysts projecting a loss of $0.60 per share and revenue of $24.35 million. This follows a Q2 miss where the company reported an $0.81 loss per share against an expected $0.73 loss, and revenue of $9.04 million, falling short of the $15.29 million estimate. Despite insider selling of over 21,000 shares in the last three months, analyst sentiment remains largely positive, with 13 analysts rating the stock a "Buy" and a consensus target price of $34.21 compared to its recent price of $23.71.
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
Nurix Therapeutics announced the achievement of a $7 million research milestone under its strategic collaboration with Pfizer for the discovery and development of degrader antibody conjugates (DACs). This payment brings the total received under the agreement to $82 million. The collaboration, which began in September 2023, could lead to up to $3.4 billion in potential milestone payments and tiered royalties for Nurix.
Nurix receives $7 million milestone payment from Pfizer collaboration
Nurix Therapeutics has achieved a $7 million research milestone from its collaboration with Pfizer to develop degrader antibody conjugates, bringing the total payments received to $82 million. The partnership, originally established with Seagen in September 2023, includes potential milestone payments up to $3.4 billion and future royalties. This collaboration focuses on combining targeted antibody delivery with protein degradation technology for therapeutic development.
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
Nurix Therapeutics announced the achievement of a $7 million research milestone under its strategic collaboration with Pfizer for the discovery and development of degrader antibody conjugates (DACs). This payment brings the total amount received under the agreement to $82 million. The collaboration, originally with Seagen Inc. (now part of Pfizer), could lead to up to $3.4 billion in potential milestone payments and tiered royalties for Nurix.
Pfizer will pay Nurix another $7 million, bringing its total receipts to $82 million.
Nurix Therapeutics has achieved a $7 million research milestone under its strategic collaboration with Pfizer for the development of degrader antibody conjugates (DACs). This payment increases Nurix's total receipts from the agreement to $82 million. The collaboration, which began in September 2023 with Seagen (now Pfizer), could lead to up to $3.4 billion in additional milestone payments and tiered royalties on future product sales.
Nurix Therapeutics to Receive $7 Million Pfizer Collaboration Milestone Payment
Nurix Therapeutics announced it will receive a $7 million milestone payment from Pfizer. The article, however, cuts off the full details of the collaboration, requiring a premium subscription to access the complete MT Newswires report.
PERCEPTIVE ADVISORS LLC Adds Nurix Therapeutics Inc (NRIX) -- Shares Look 197% Overvalued on GF Value
PERCEPTIVE ADVISORS LLC has increased its stake in Nurix Therapeutics Inc (NRIX) by acquiring 1,216,207 additional shares, making it a significant allocation in their healthcare-focused portfolio. Despite the firm's conviction in the clinical-stage biopharmaceutical company's pipeline, Nurix Therapeutics is classified as "Significantly Overvalued" by GuruFocus, trading at roughly 197% above its intrinsic value. The company exhibits strong growth potential but struggles with profitability, reflected in negative ROE and ROA, alongside a low Piotroski F-Score.
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Has Consensus Price Target of $34.21 According to Analysts
Nurix Therapeutics, Inc. (NASDAQ:NRIX) has a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $34.21, significantly above its current reported price of $23.01. Despite a recent downgrade by Wells Fargo and a "sell" rating from Weiss Ratings, other analysts like RBC, UBS, and BTIG Research have either raised price targets or reiterated "buy" ratings. The company recently reported weaker-than-expected quarterly results, missing both EPS and revenue estimates, and insiders have sold over $518,000 worth of shares in the last 90 days.
Nurix Therapeutics (NASDAQ:NRIX) Upgraded to "Hold" at Wall Street Zen
Wall Street Zen has upgraded Nurix Therapeutics (NASDAQ:NRIX) from "Sell" to "Hold," though the broader analyst consensus remains a "Moderate Buy" with an average price target of $34.21. This upgrade follows a period where the company's shares opened down 2.7%, and its latest quarterly results missed expectations, reporting an adjusted loss of $0.81 per share and revenue of $9.04 million. Despite insider stock sales totaling over $500,000 in the last three months, several institutional investors have initiated new positions in the company.
842,089 Shares in Nurix Therapeutics, Inc. $NRIX Bought by Bank of America Corp DE
Bank of America Corp DE recently acquired 842,089 shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) in the second quarter, a stake valued at approximately $20.4 million. This acquisition makes Bank of America a significant shareholder, owning 0.81% of the company. Despite positive analyst sentiment with a "Moderate Buy" rating, Nurix Therapeutics reported a quarterly loss of $0.81 per share and revenue of $9.04 million, both below analyst expectations, and company insiders have sold shares totaling over $500,000 in the last 90 days.
Nurix Therapeutics (NRIX) Short Interest & Short Float | Updated Sep 2026
This article details the short interest and short float for Nurix Therapeutics (NRIX) as of September 15, 2026. The company had 17.98 million shares sold short, representing 18.57% of its public float, marking a slight increase of 0.15% from the previous report. The short interest ratio stands at 14.1 days to cover, indicating a strong pessimistic sentiment among investors.
More than 5% of Nurix Therapeutics (NRIX) is reported by three parties, but one fund holds the shares.
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have each reported a 5.3% beneficial ownership stake in Nurix Therapeutics (NRIX), totaling 5,536,629 shares. The shares are directly held by Perceptive Life Sciences Master Fund, Ltd., with Perceptive Advisors acting as its investment manager and Joseph Edelman as Perceptive Advisors' managing member. This disclosure is based on 103,781,683 NRIX shares outstanding as of June 30, 2026.
Nurix Therapeutics Stock Price Forecast. Should You Buy NRIX?
Nurix Therapeutics (NRIX) has been downgraded to a Sell Candidate with a technical score of -3.31, according to StockInvest.us, based on market data through September 11, 2026. Despite a positive 3-month trend forecast of a 34.69% rise, the stock exhibits several negative technical signals, including sell signals from Moving Averages and MACD, and a recent price fall. The company, which focuses on small molecule therapies for cancer and immune disorders, is expected to have low risk due to good trading volume and minor daily changes, but investors are advised to hold off on buying until the stock price is closer to support levels.
Here's Why You Should Add NRIX Stock to Your Portfolio Now
Nurix Therapeutics (NRIX) is highlighted as a strong buy due to its lead product candidate, bexobrutideg, an oral BTK degrader for B-cell malignancies, with potential expansion into immunology and neurology. A key factor is its global collaboration with Roche, valued at up to $2.3 billion, which validates bexobrutideg's potential and shares development costs. The article also mentions Nurix's progress in clinical trials, expansion into new therapeutic areas, and other strategic partnerships.
Legal & General Group Plc Buys Shares of 72,026 Nurix Therapeutics, Inc. $NRIX
Legal & General Group Plc recently acquired a new position in Nurix Therapeutics, Inc., purchasing 72,026 shares valued at approximately $1.75 million. This transaction highlights increased institutional investor interest in Nurix Therapeutics, although some insiders have sold shares recently. Analysts currently rate Nurix Therapeutics with a "Moderate Buy" consensus, forecasting future growth.
Bank of New York Mellon Corp Purchases New Shares in Nurix Therapeutics, Inc. $NRIX
Bank of New York Mellon Corp recently acquired 272,640 shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the second quarter, valued at approximately $6.6 million. Despite this new institutional interest, Nurix Therapeutics reported an adjusted quarterly loss of $0.81 per share, missing consensus estimates, and insiders have sold a significant number of shares recently. Analysts currently have a "Moderate Buy" consensus rating for NRIX with an average price target of $34.21, though some firms have downgraded the stock.
Nurix Therapeutics chief legal officer sells over $149k in shares By Investing.com
Christine Ring, Chief Legal Officer at Nurix Therapeutics, Inc., sold 5,787 shares of common stock for over $149,000 on September 2, 2026, while also acquiring the same number of shares through employee stock options. The transactions were conducted under a pre-arranged trading plan. The stock has seen a significant 173% return over the past year, and analysts maintain a positive outlook, partly due to the company's collaboration deal with Roche.
Nurix Therapeutics chief legal officer sells over $149k in shares
Nurix Therapeutics' Chief Legal Officer, Christine Ring, sold 5,787 shares of common stock for over $149,000, executed under a Rule 10b5-1 trading plan. Concurrently, Ring acquired the same number of shares through the exercise of employee stock options. The company's stock has seen a 173% return over the past year, and analysts maintain a positive outlook, partly due to a collaboration deal with Roche.
The Manufacturers Life Insurance Company Acquires New Holdings in Nurix Therapeutics, Inc. $NRIX
The Manufacturers Life Insurance Company has acquired a new stake of 168,857 shares in Nurix Therapeutics, valued at approximately $4.1 million. This acquisition comes as Nurix Therapeutics reported weaker-than-expected quarterly results, missing consensus estimates for both earnings per share and revenue. Despite the mixed financial performance, analysts maintain a "Moderate Buy" rating for NRIX, with an average price target of $34.21, although insider selling has also been noted.
Man Group plc Makes New $2.08 Million Investment in Nurix Therapeutics, Inc. $NRIX
Man Group plc initiated a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX), purchasing 85,583 shares valued at approximately $2.08 million during the second quarter. Despite this new investment and other institutional interest, Nurix Therapeutics missed analyst expectations for its recent quarterly earnings and revenue. However, analysts maintain a "Moderate Buy" consensus rating for the stock, with an average price target above its current trading price.
Alyeska Investment Group L.P. Takes $3.35 Million Position in Nurix Therapeutics, Inc. $NRIX
Alyeska Investment Group L.P. has acquired a new position in Nurix Therapeutics (NASDAQ:NRIX) worth approximately $3.35 million, joining several other institutional investors. Despite broad analyst positivity with a "Moderate Buy" consensus and an average price target of $34.21, Nurix recently missed analyst estimates for earnings and sales, reporting a quarterly loss of $0.81 per share and $9.04 million in revenue. Additionally, company insiders have sold over $626,000 worth of shares in the past 90 days.
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
Nurix Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced its participation in four upcoming investor conferences in September 2026. The company management will engage in fireside chats at the Wells Fargo, H.C. Wainwright, Baird, and Morgan Stanley Healthcare Conferences. These sessions will be webcast live and archived on Nurix's investor relations website.
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced its participation in several investor conferences in September 2026, including the Wells Fargo, H.C. Wainwright, Baird, and Morgan Stanley Healthcare Conferences. Company management will conduct fireside chats at these events, which will be webcast live and archived on Nurix's investor website. Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines for cancer and autoimmune diseases.
BlackRock Inc. Buys New Position in Nurix Therapeutics, Inc. $NRIX
BlackRock Inc. has acquired a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX), purchasing 8.77 million shares valued at $212.8 million, representing an 8.45% stake. Despite this significant institutional investment and a "Moderate Buy" consensus rating from analysts, Nurix Therapeutics reported weaker-than-expected quarterly results with an EPS miss and lower revenue. The company remains unprofitable, with analysts projecting a full-year loss, and recent insider selling has also been noted.
Trails Edge Capital Partners LP Purchases New Holdings in Nurix Therapeutics, Inc. $NRIX
Trails Edge Capital Partners LP has acquired a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the second quarter, purchasing over 1.5 million shares valued at approximately $38.1 million, making it their second-largest holding. This comes as other institutional investors have also modified their positions in NRIX, and company insiders have recently sold shares. Nurix Therapeutics stock performance and analyst ratings are also detailed, with a consensus "Moderate Buy" rating.
Elmind Capital LP Invests $11.16 Million in Nurix Therapeutics, Inc. $NRIX
Elmind Capital LP has acquired a new stake of 460,000 shares, valued at approximately $11.16 million, in Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the second quarter, making it their 14th largest holding. Other institutional investors have also adjusted their positions in Nurix Therapeutics. The article also details Nurix Therapeutics' stock performance, recent earnings, analyst ratings, and insider transactions, noting a consensus "Moderate Buy" rating with a target price of $34.21.
313,236 Shares in Nurix Therapeutics, Inc. $NRIX Acquired by ADAR1 Capital Management LLC
ADAR1 Capital Management LLC has acquired 313,236 shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) worth approximately $7.6 million during the second quarter. Despite missing quarterly earnings and revenue expectations, analysts maintain a "Moderate Buy" rating for NRIX with a consensus price target of $34.21. Insider selling has also occurred, with Gwenn Hansen and Houte Hans Van selling shares.
Deutsche Bank AG Takes Position in Nurix Therapeutics, Inc. $NRIX
Deutsche Bank AG has acquired a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX), purchasing 151,453 shares valued at approximately $3.67 million. This makes Deutsche Bank AG a significant shareholder, owning 0.15% of the company. Other institutional investors have also adjusted their stakes, while company insiders have recently sold shares, though insiders still own 6.70% of Nurix Therapeutics.
58,898 Shares in Nurix Therapeutics, Inc. $NRIX Bought by Polymer Capital Management HK LTD
Polymer Capital Management HK LTD recently acquired 58,898 shares of Nurix Therapeutics (NASDAQ:NRIX) worth approximately $1.43 million. This comes as other institutional investors, including BlackRock Inc., also established significant new positions in the company. Despite positive analyst sentiment with a "Moderate Buy" consensus and an average price target of $34.21, Nurix Therapeutics reported weaker-than-expected quarterly results, and insiders have sold shares under pre-arranged trading plans.
Bank of America Corp DE Purchases 65,595 Shares of Nurix Therapeutics, Inc. $NRIX
Bank of America Corp DE increased its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 8.9% in the first quarter, acquiring an additional 65,595 shares and now owning 802,153 shares valued at $12.43 million. Other institutional investors also adjusted their positions in the company, while several analysts have issued ratings and price targets for NRIX, with a consensus of "Moderate Buy" and a target price of $34.21. Recent insider selling activity by CFO Houte Hans Van and Gwenn Hansen was also reported.
Edmond DE Rothschild Holding S.A. Invests $2.18 Million in Nurix Therapeutics, Inc. $NRIX
Edmond DE Rothschild Holding S.A. has invested $2.18 million in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by purchasing 90,000 shares in the second quarter, representing a 0.09% stake. This comes amidst other institutional investments and a "Moderate Buy" consensus from analysts with an average price target of $34.21, despite the company missing earnings and revenue estimates for its latest quarter. Insider selling also occurred, with two executives selling shares worth over $220,000 combined.
Deep Track Capital, LP Expands Nurix Therapeutics Inc (NRIX) Sta
Deep Track Capital, LP increased its stake in Nurix Therapeutics Inc (NRIX) by purchasing 1,391,211 shares, bringing its total holdings to 7,736,455 shares. Nurix Therapeutics, a clinical-stage biopharmaceutical company, is considered significantly overvalued by GuruFocus's GF Value, trading at 286% above its intrinsic value despite strong market momentum. Deep Track Capital's move aligns with its strategy of investing in high-potential biotech firms, while financial health indicators for Nurix show strong liquidity but ongoing unprofitability.
Press Release: Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
Nurix Therapeutics has announced the appointment of Wes Burwell as its new Chief Human Resources Officer. Burwell brings extensive experience in HR leadership within the biotechnology and pharmaceutical sectors. This strategic hire aims to strengthen Nurix's organizational development and talent strategy as it continues to advance its drug discovery programs.
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
Nurix Therapeutics has appointed Wes Burwell as its new Chief Human Resources Officer. Burwell brings over 20 years of HR leadership experience in the life sciences sector, with a strong background in scaling organizations through growth and preparing for commercialization. His appointment comes as Nurix transitions from a research-focused company to a fully integrated biopharmaceutical organization, aiming to advance its clinical pipeline and prepare for the commercial launch of its targeted protein degradation medicines.
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
Nurix Therapeutics (Nasdaq: NRIX) has appointed Wes Burwell as its new Chief Human Resources Officer. Burwell brings over 20 years of HR leadership experience in life sciences and will join the company's Executive Management Team. His role will be crucial as Nurix transitions from a research and early clinical-stage company to a fully integrated biopharmaceutical organization, preparing for commercialization and scaling its operations.
Nurix Therapeutics (NRIX) Starts Phase 3 And Lands Sanofi Milestone, Is The Valuation About Right?
Nurix Therapeutics (NRIX) has seen increased investor attention following the start of a Phase 3 trial for bexobrutideg and a $10 million milestone payment from Sanofi. The stock has experienced significant positive momentum over the past year. While its Price-to-Book ratio of 7x appears rich compared to the broader biotech industry, it is cheaper than its direct peer group, suggesting a balanced market valuation despite ongoing losses.
Handelsbanken Fonder AB Buys 86,000 Shares of Nurix Therapeutics, Inc. $NRIX
Handelsbanken Fonder AB increased its stake in Nurix Therapeutics (NASDAQ:NRIX) by 15.7% in the second quarter, acquiring an additional 86,000 shares, bringing its total holdings to 633,000 shares valued at approximately $15.4 million. Despite this institutional buying, insiders sold a significant number of shares, and Nurix reported quarterly earnings and revenue below analyst expectations. Analyst sentiment remains "Moderate Buy" with a consensus price target of $34.21, although some analysts have adjusted their ratings and price targets.
Nurix Therapeutics (NRIX) Is Up 6.0% After Milestone From Sanofi And Phase 3 Start With Roche
Nurix Therapeutics (NRIX) saw its stock rise 6.0% after achieving a US$10 million milestone payment from Sanofi for advancing its oral STAT6 degrader into a Phase 1 trial. Concurrently, the company, in partnership with Roche, began a global Phase 3 study for its BTK degrader bexobrutideg, enrolling the first patient for relapsed or refractory CLL/SLL. These developments highlight Nurix's DEL-AI platform's progress into late-stage clinical programs and its ability to generate partnership revenues.
Nurix Therapeutics (NRIX) Is Up 6.0% After Milestone From Sanofi And Phase 3 Start With Roche
Nurix Therapeutics received a US$10 million milestone payment from Sanofi for advancing an oral STAT6 degrader into a Phase 1 trial and initiated a global Phase 3 study with Roche for its BTK degrader bexobrutideg. These developments highlight the progression of Nurix's DEL-AI platform into late-stage clinical programs and demonstrate tangible partnership revenues. The company's investment narrative is centered on its platform translating into clinical success and non-dilutive funding, with the Roche collaboration providing a significant registrational-stage catalyst.
Nurix Therapeutics stock hits 52-week high at $26.40 By Investing.com
Nurix Therapeutics (NRIX) stock has reached a 52-week high of $26.40, marking a 1-year return of 159%, and is currently trading near its Fair Value with a market capitalization of $2.72 billion. Analysts predict the company will achieve profitability this year with an expected EPS of $3.80. Recent analyst updates from Mizuho, Truist Securities, Baird, and Morgan Stanley reflect strong confidence, particularly due to a significant collaboration deal with Roche for the drug bexdeg, leading to raised price targets.
Nurix Therapeutics (NRIX) Is Up 6.0% After Milestone From Sanofi And Phase 3 Start With Roche
Nurix Therapeutics (NRIX) saw a 6.0% stock increase after announcing a US$10 million milestone payment from Sanofi for advancing an oral STAT6 degrader into a Phase 1 trial and enrolling the first patient in a global Phase 3 study for its BTK degrader bexobrutideg with Roche. These developments highlight the success of Nurix’s DEL-AI protein degradation platform in generating late-stage clinical programs and partnership revenues. While the Sanofi payment is small compared to Nurix's R&D spend, it de-risks the platform, with future BTK degrader data and milestones from Roche and Sanofi remaining key factors for investors.
Nurix Therapeutics stock hits 52-week high at $26.40
Nurix Therapeutics Inc. (NRIX) stock has reached a new 52-week high of $26.40, marking a 159% return over the past year. Analysts expect the company to be profitable this year, with EPS projected at $3.80, and major firms like Mizuho, Truist Securities, Baird, and Morgan Stanley have raised price targets following a collaboration deal with Roche.
Sei Investments Co. Buys 46,132 Shares of Nurix Therapeutics, Inc. $NRIX
Sei Investments Co. significantly increased its stake in Nurix Therapeutics (NASDAQ:NRIX) during the first quarter, purchasing an additional 46,132 shares and bringing its total holdings to 82,108 shares valued at $1.27 million. Despite recent weaker-than-expected quarterly earnings and insider share sales, analysts largely maintain a "Moderate Buy" consensus rating with an average price target of $34.21, significantly above the stock's current trading price. Several other institutional investors also established or expanded their positions in Nurix Therapeutics.
Renaissance Technologies LLC Invests $1.83 Million in Nurix Therapeutics, Inc. $NRIX
Renaissance Technologies LLC recently acquired a new position in Nurix Therapeutics, Inc. worth approximately $1.83 million during the first quarter. Despite this institutional investment and a "Moderate Buy" consensus rating from analysts, Nurix Therapeutics reported weaker-than-expected quarterly results, including an EPS loss of $0.81 against an estimated $0.73, and revenue significantly below expectations. Additionally, company insiders have sold over 25,000 shares in the last three months.
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year High After Analyst Upgrade
Nurix Therapeutics (NASDAQ:NRIX) reached a new 52-week high after Royal Bank of Canada raised its price target from $33 to $36, maintaining an "outperform" rating. Despite positive analyst sentiment with a "Moderate Buy" consensus, the company continues to report financial losses, missing revenue and EPS expectations in its latest quarterly results. Insiders have also recently sold shares, though institutional investors have shown mixed activity, with some increasing their holdings.
Royal Bank Of Canada Boosts Nurix Therapeutics (NASDAQ:NRIX) Price Target to $36.00
Royal Bank of Canada increased its price target for Nurix Therapeutics (NASDAQ:NRIX) from $33.00 to $36.00, maintaining an "outperform" rating, indicating a potential 40.7% upside. This adjustment comes despite the company missing quarterly earnings and revenue estimates, and notable insider selling. Overall analyst sentiment remains positive, with a "Moderate Buy" consensus and an average price target of $34.21.
Why Nurix Therapeutics (NRIX) Is Back In The Spotlight
Nurix Therapeutics (NRIX) is gaining investor attention following the enrollment of the first patient in its Phase 3 DAYBreak CLL-306 trial for bexobrutideg and a $10 million milestone payment from Sanofi. The company has seen significant share price appreciation over the past year, although its price-to-book ratio of 6.6x suggests it's expensive compared to the broader US Biotechs industry average, yet appears reasonable against a closer peer group. Investors are weighing the potential rewards from clinical progress against risks such as ongoing losses and trial outcomes.
